Navigation Links
Empire Genomics Chooses Funakoshi as Japan Distributor
Date:4/24/2012

BUFFALO, N.Y., April 24, 2012 /PRNewswire-iReach/ -- Empire Genomics today announced that it has chosen Funakoshi as a distributor of its product portfolio for the Japanese market.  The deal represents Empire's international expansion and importance of growth in the region.

"We are excited to have such a proven and expert partner in Funakoshi to service our Japanese customers and offer access to our broad genomic product and service portfolio," said Anthony Johnson, President and CEO of Empire Genomics. "I am confident this relationship will provide customers with the excellent support and high quality service  our customers have come to expect."   

"We are delighted with Empire Genomics agreement. Empire Genomics perfectly complements our portfolio range of high quality products and services. Empire Genomics portfolio provides Funakoshi Company the opportunity to meet high demands for basic bioscience research and also for the pharmaceutical research in Japan." said Dr.Ryoya Funakoshi, President & CEO of Funakoshi Company, Ltd.

Financial terms of the deal were not disclosed.

About Empire Genomics, LLC

Empire Genomics delivers the most advanced genomic tools to aid the scientific community in its research and diagnostic challenges. Through many years of experience in the area of  genomics and working with diverse sample types, we are able to provide continuous innovation for research and diagnostic applications in areas of oncology, biomarkers, drug discovery, constitutional disorders, developmental disorders and autism, among many others.

About Funakoshi Co. Ltd.

Funakoshi Co., Ltd. has contributed as a leader to distribute research reagents and instruments for researchers in life science fields since its foundation. The mission of Funakoshi is offering many useful tools with leading edge technologies for Japanese researchers from all over the world to support and develop their research. For more information, visit Funakoshi's website: www.funakoshi.co.jp.

Media Contact:

Sonya Stutts Empire Genomics, LLC, 716-856-3873, sonya.stutts@empiregenomics.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Empire Genomics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Alert -- Empire Asset Management Co. Initiates Coverage on Pacira Pharmaceuticals Inc. (NASDAQ: PCRX)
2. Empire BlueCross BlueShield Expands Lab Networks -- Creating Broader Choice, Robust Competition and Lower Costs for Consumers
3. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
4. Everist Genomics Develops Worlds First Comprehensive Companion Diagnostics and Prognostics Portfolio for Early Diagnosis and Improved Treatment of Colorectal Cancer
5. Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
6. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
7. Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology
8. Smartphone Technology Meets Personalized Medicine in Everist Genomics CardioDefender Diagnostic System
9. AccuGenomics to Attend OneMedForum with Standardized Gene Expression Tests for Leukemia and Lung Cancer
10. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
11. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Blueprint Medicines Corporation (NASDAQ: BPMC ... kinase medicines for patients with genomically defined diseases, ... trial evaluating BLU-285, an investigational medicine for the ... Blueprint Medicines is developing BLU-285 as a potent, ... 90 to 95 percent of patients with SM ...
(Date:12/4/2016)... HANOVER, N.J. , Dec. 3, 2016  Results ... (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median ... 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in ... today announced that the data are being featured in ... American Society of Hematology (ASH) Annual Meeting and presented ...
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test para el mercado africano ... Continue Reading ... New: INSTI Self Test! (PRNewsFoto/bioLytical ... bioLytical Laboratories (la "Compañía"), un líder mundial en ... de su INSTI HIV Self Test  a África con una versión de menor ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... The ... assistants, under direct supervision of a licensed physical therapist, to render care for ... consultation and treatment plan from a licensed physical therapist (PT) and throughout the ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic ... Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading ...
(Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony ... more tools allowing FCPX editors to create professional looking video in a matter ... Perfect Harmony contains a beautifully designed 3D environment for placing in personal media. ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients ... can now take advantage of a cosmetic procedure known as Carbon Dioxide ... reduces the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, ...
(Date:12/2/2016)... ... 2016 , ... Two years ago, Arizona State University students ... by 1 million viewers and won numerous honors, including the region’s top Emmy ... Walter Cronkite School of Journalism and Mass Communication are following up their award-winning ...
Breaking Medicine News(10 mins):